We are testing new coms techniques, please bear with us as some of our posts may be a bit strange.

This week in biotech: major AI-driven therapeutic breakthroughs, business alliances for gene and cell therapies, and advances in next-gen drug platforms. 💰 Business: . • Gilead acquires Interius Bio for $350M, expanding into in vivo cell therapies for cancer and immune

What do you want to know?.

This week in biotech: major regulatory moves for clinical trial access, new neuro drug deals, and AI’s rising impact on mental health. 💰 Business:. • Jazz Pharma licenses Saniona’s selective epilepsy drug, aiming to expand its CNS portfolio in a competitive market. Builds

This week in biotech: breakthrough clinical advances, business shakeups, and novel uses of AI reinforce momentum across the sector. 💰 Business:. • Insmed’s Brinsupri wins FDA approval, prompting stock surge and blockbuster forecasts. Signals major commercial success for rare

This week in biotech: AI drives major advances from cancer treatments to rapid drug discovery, alongside strong business momentum. 💰 Business: . • Insmed’s Brinsupri nabs FDA approval, igniting analyst blockbuster forecasts and a 17% stock surge. Signals high market optimism

This week in biotech: blockbuster approvals energize markets, while AI and engineered microbes drive next-gen therapies. 💰 Business:. • Insmed’s Brinsupri earns FDA approval, with analysts forecasting blockbuster sales and shares surging 17%. Signals investor confidence in

Biotech this week: major cancer trial milestones, fresh antiviral strategies, and new tools unlocking disease mechanisms. ⚕️ Clinical and Discovery:. • mRNA-based broad-spectrum antiviral, inspired by a rare immune disorder, shows activity against diverse viruses including

This week in biotech: major clinical shifts for cancer, advances in anti-infective discovery, and deepened insight into tumor biology. ⚕️ Clinical and Discovery: . • Schrödinger halts cancer drug program after two patient deaths in Phase I AML trial. Highlights safety risks in

This week in biotech: hard-hitting clinical trial results, promising immunotherapy advances, and new regulatory milestones. 💰 Business:. • Absci and Almirall expand AI-driven dermatology partnership, potentially worth up to $650M. Accelerates tough-to-drug antibody pipeline.

This week in biotech: landmark R&D deals, precision AI breakthroughs, regulatory crackdowns, and new directions in disease therapy. 💰 Business: . • Absci and Almirall expand an AI-driven dermatology antibody partnership up to $650M. Highlights rising AI impact in hard-to-drug

Biotech this week: major FDA actions, novel therapies for tough diseases, and tech-driven advances in care and discovery. 💰 Business:. • Navitus and Costco Pharmacy launch cost-plus prescription pricing, broadening drug affordability and transparency nationwide.

This week in biotech: innovative brain studies advance movement disorder insights, while new platforms may accelerate protein and vaccine design. ⚕️ Clinical and Discovery: . • Rat brain study deciphers neural codes for learned vs. innate movements, advancing understanding of

Innovation in biotech surged this week: major funding rounds, new partnerships, and regulatory shifts drive advances from cancer screening to next-gen therapies. 💰 Business:. • Exact Sciences partners with Freenome on a blood test to rival Guardant Health for colorectal cancer

This week in biotech: major deals and bold M&A moves shake up the landscape, while innovation accelerates in protein engineering and universal vaccines. 💰 Business: . • 10x Genomics to acquire Scale Biosciences, expanding its single-cell genomics toolkit for deeper biological

another beautiful glitch.

This week in biotech: major FDA nods, high-impact acquisitions, advancement in protein engineering, and notable regulatory shifts. 💰 BUSINESS: .1️⃣ BioNTech to pay CureVac, GSK $740M to settle mRNA patent disputes—paves way for BioNTech's $1.25B CureVac acquisition and resets

A transformative week for biotech: major clinical wins, regulatory shifts, landmark deals, and advances in disease research. 💰 BUSINESS: .1️⃣ BioNTech will pay CureVac & GSK $740M+ to settle mRNA patent disputes, paving the way for BioNTech’s $1.25B CureVac acquisition.

This week in biotech: Pain drug setbacks, innovative neuro and infection therapies, major R&D shakeups, and strong funding momentum shape the landscape. 💰 BUSINESS: .1️⃣ Datavant acquires Ontellus, expanding into legal and insurance data. Signals growing convergence of health,

Tumor-targeting bacteria, regulatory shifts, and next-gen gene therapies dominate a landmark week in biotech. 💰 BUSINESS: .1️⃣ Ocugen pursues 3 BLAs for eye gene therapies, aiming to succeed where others stalled. Could reshape commercial AAV therapy in ophthalmology.

This week in biotech: transformative trial results, robust investments, and regulatory shifts highlight a fast-changing landscape. 💰 BUSINESS: .1️⃣ Seaport, Vilya, and Freya Biosciences draw major early-stage funding, energizing CNS, macrocycle, and women’s health pipelines.

Sometimes glitches produce beautiful things, whether in DNA or code